Concepedia

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

Marc Ferrante, Julien Fahed

The Lancet · 2024 · 102 citations · 17 references

DOIFull text

Open access

Concepts

References

17

A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene

Richard H. Duerr, Kent D. Taylor, Steven R. Brant et al. · Science · 2006 · 3K citations · Full text

, , +17

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

Fernando Gomollón, Vito Annese, Herbert Tilg et al. · Journal of Crohn s and Colitis · 2016 · 2.1K citations · Full text

, , +16

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

Brian G. Feagan, William J. Sandborn, Christopher Gasink et al. · New England Journal of Medicine · 2016 · 1.8K citations · Full text

, , +17

ACG Clinical Guideline: Management of Crohn's Disease in Adults

Gary R. Lichtenstein, Edward V. Loftus, Kim L. Isaacs et al. · The American Journal of Gastroenterology · 2018 · 1.4K citations

, , +12

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

Geert D’Haens, Remo Panaccione, Filip Baert et al. · The Lancet · 2022 · 387 citations · Full text

, , +9